Research Monitoring
What changed
in the evidence.
Evidence is not static, and neither are our grades. This is the public log of what moved — new trials, regulatory actions, and every time we changed a compound's grade, with the source that prompted it.
Recent trial changes
Detected between ClinicalTrials.gov syncs · 2026-10-15FutureShape Family
Added to Synptide tracking
Semaglutide vs Sitagliptin
Added to Synptide tracking
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
Not yet recruiting → Recruiting
A Study of BGM0504 in Early T2DM With Obesity
Added to Synptide tracking
A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum
Added to Synptide tracking
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)
Added to Synptide tracking
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
Added to Synptide tracking
A Study to Evaluate ALN-2232 in Participants With Obesity
Added to Synptide tracking
Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes
Added to Synptide tracking
ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy Aging
Added to Synptide tracking
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
Added to Synptide tracking
Semaglutide for Helping Opioid Recovery
Added to Synptide tracking
Recent trial activity
Auto-updated from ClinicalTrials.gov · synced 2026-10-15FutureShape Family
Semaglutide vs Sitagliptin
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
A Study of BGM0504 in Early T2DM With Obesity
A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
A Study to Evaluate ALN-2232 in Participants With Obesity
Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes
Evidence-grade change log
July 2026
Synptide launches the compound directory and evidence-grading system
We published canonical, outcome-graded profiles for the first 25 compounds, plus a public A–U evidence framework and this change log.
Semaglutide graded A for cardiovascular risk reduction on SELECT evidence
We set semaglutide's cardiovascular-outcome grade to A after the SELECT trial's 20% reduction in major cardiovascular events.